Skip to content

Iluvien fluocinolone approved by the Scottish Medicines Board for restricted use on the NHS

Alimera Sciences, Inc. (NASDAQ: ALIM), Alpharetta, GA, has announced the receipt of a recommendation decision from the Scottish Medicine’s Board for the restricted use of the Iluvien fluocinolone acetonide intravitreal implant to treat vision impairment associated with chronic diabetic macular edema (DME) considered insufficiently responsive to available therapies. The injectable insert has previously received approval to treat chronic DME considered insufficiently responsive to available therapies in the UK, Portugal, France, Germany and Austria.